Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

111.96USD
2 Dec 2016
Change (% chg)

$0.58 (+0.52%)
Prev Close
$111.38
Open
$111.81
Day's High
$112.53
Day's Low
$111.45
Volume
2,095,037
Avg. Vol
2,257,628
52-wk High
$126.07
52-wk Low
$94.30

Select another date:

Fri, Dec 2 2016

Photo

Actelion's silence has hedge funds betting big on J&J deal

ZURICH Actelion's silence speaks volumes to the dozens of event-driven hedge funds piling into the Swiss biotech firm, betting that Johnson & Johnson's (J&J) approach will result in an outright takeover and handsome returns.

Johnson & Johnson hit with over $1 billion verdict on hip implants

A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants.

Actelion shares fall on report it rejects J&J offer

ZURICH Shares in Swiss biotech company Actelion fell more than 6 percent after news outlet streetinsider.com reported on Wednesday the company had rejected a full takeover offer by U.S. healthcare group Johnson & Johnson and may sell a unit.

Rejecting J&J could leave Actelion with 'lot of explaining to do'

ZURICH/LONDON Some Actelion shareholders would be attracted by a $27 billion bid for the Swiss biotech company from Johnson & Johnson, leaving Chief Executive Jean-Paul Clozel with some explaining to do if he turned down an offer around that level.

Deals of the day-Mergers and acquisitions

Nov 29 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:

J&J raises Actelion takeover pressure with higher price: source

LONDON U.S. healthcare company Johnson & Johnson has raised its offer for Actelion, a source told Reuters on Tuesday, stepping up pressure on the Swiss biotech firm to accept a takeover deal.

Actelion shares plunge on report it eyes 'complicated' J&J deal

ZURICH Shares in Swiss biotech company Actelion plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a "complicated deal" to link with U.S. healthcare giant Johnson & Johnson .

Actelion shares plunge on report it eyes "complicated" J&J deal

ZURICH, Nov 29 Shares in Swiss biotech company Actelion plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a "complicated deal" to link with U.S. healthcare giant Johnson & Johnson.

Biotech group Actelion, Johnson & Johnson confirm deal talks

ZURICH/FRANKFURT U.S. healthcare company Johnson & Johnson said on Friday it was in preliminary talks with Actelion about a potential takeover of Europe's largest biotech firm, currently valued at about $20 billion.

Johnson & Johnson approaches Actelion about takeover deal

ZURICH/FRANKFURT U.S. healthcare company Johnson & Johnson said on Friday it was in preliminary talks with Actelion about a potential takeover of Europe's largest biotech firm, currently valued at about $20 billion.

Select another date: